Quadrisol

RSS

vedaprofen

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Quadrisol. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Quadrisol.

For practical information about using Quadrisol, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 24/08/2017

Authorisation details

Product details
Name
Quadrisol
Agency product number
EMEA/V/C/000032
Active substance
vedaprofen
International non-proprietary name (INN) or common name
vedaprofen
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AE90
Publication details
Marketing-authorisation holder
VETCOOL B.V.
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
04/12/1997
Contact address
Otto Hahnweg 24
3542 AX Utrecht
Netherlands

Product information

25/04/2017 Quadrisol - EMEA/V/C/000032 - T/0037

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Not yet assigned

Therapeutic indication

Reduction of inflammation and relief of pain associated with musculoskeletal disorders and soft-tissue lesions (traumatic injuries and surgical trauma). In cases of anticipated surgical trauma, Quadrisol can be given prophylactically at least three hours prior to elective surgery.

Assessment history

How useful was this page?

Add your rating